Change Password!
Reset Password!
Globally, an estimated 1.55 million females of reproductive age are affected by Polycystic Ovary Syndrome (PCOS), contributing to approximately 0.43 million disability-adjusted life years.
Emphasizing patient education, shared decision-making, and minimizing weight bias, the Revised 2023 Guidelines for PCOS recommend combined oral contraceptives for menstrual irregularity and hyperandrogenism, Letrozole for infertility, and IVF with single embryo transfer as third-line therapy.
Comments (0)